远切缘不规则(适形)切除在极低位直肠癌功能保肛中的价值

房忠轩,  朱晓明,  张卫,  于冠宇

引用本文: 房忠轩,朱晓明,张卫,等.远切缘不规则(适形)切除在极低位直肠癌功能保肛中的价值[J].海军军医大学学报,2026,47(9):1165-1172.DOI: 10.16781/j.CN31-2187/R.20260280.
Citation: Fang Z, Zhu X, Zhang W, et al. Value of irregular(conformal)distal-margin resection in functional sphincter preservation for ultra-low rectal cancer[J]. Acad J Naval Med Univ, 2026, 47(9): 1165-1172. DOI: 10.16781/j.CN31-2187/R.20260280.

远切缘不规则(适形)切除在极低位直肠癌功能保肛中的价值

doi: 10.16781/j.CN31-2187/R.20260280
基金项目: 

上海市卫生健康委员会卫生行业临床研究专项 20254Y0178;

海军军医大学医疗新技术创新培育项目 ZXJS2024C05;

海军军医大学第一附属医院临床新技术孵育项目 2024XA001.

详细信息

Value of irregular (conformal) distal-margin resection in functional sphincter preservation for ultra-low rectal cancer

Funds: 

Clinical Research Program of Healthcare Industry of Shanghai Municipal Health Commission 20254Y0178;

Novel Medical Technology Innovation Cultivation Program of Naval Medical University ZXJS2024C05;

Clinical New Technology Incubation Program of The First Affiliated Hospital of Naval Medical University 2024XA001.

  • 摘要:

    极低位直肠癌的外科治疗面临着肿瘤根治与功能保留的艰难平衡。本文围绕极低位直肠癌功能保肛的瓶颈,系统阐述了远切缘不规则(适形)切除的理论依据与临床价值,提出该术式可作为功能保肛的核心策略。远切缘不规则(适形)切除通过个体化、适形化的精准切除,在确保肿瘤根治的前提下最大限度保留肠管和括约肌,显著改善术后肛门功能。随着新辅助治疗、免疫治疗及手术技术的发展,该策略为极低位直肠癌患者实现兼顾肿瘤根治与保留功能的治疗目标提供了方向,其理论体系的完善有望成为未来功能保肛手术的必由之路。

     

    Abstract:

    The surgical management of ultra-low rectal cancer faces a challenging balance between oncological radicality and functional preservation. This review focuses on the bottleneck of functional sphincter preservation for ultra-low rectal cancer, systematically elaborates the theoretical basis and clinical value of irregular (conformal) distal-margin resection, and proposes this approach as the core strategy for functional sphincter preservation. This approach employs personalized and conformal precision excision to maximize the preservation of intestinal tissue and sphincter muscles while ensuring oncological radicality, thereby significantly improving postoperative anal function. With advances in neoadjuvant therapy, immunotherapy, and surgical techniques, this strategy provides a framework for balancing radical tumor control and functional preservation in patients with ultra-low rectal cancer. The evolution of this concept is expected to pave a way for future sphincter-preserving surgery.

     

  • 极低位直肠癌(肿瘤下缘距肛缘≤5 cm)的外科治疗始终面临肿瘤根治与肛门功能保留的艰难平衡[1]。肛门功能的保留程度是决定极低位直肠癌患者术后生活质量的关键指标,已成为结直肠外科领域的重要研究方向之一。随着微创外科技术的发展、新辅助治疗体系的完善及盆底解剖认知的不断深化,极低位直肠癌保肛率显著提高,治疗理念也从单纯追求解剖学保肛转向以根治为基础、以保功能为核心的保肛目标[2–5]。

    为解决传统保肛术式根治与功能难以兼顾的临床瓶颈,国内外学者在经典术式的基础上持续创新,旨在进一步实现R0切除与功能保肛的双重目标。包括本团队在内,国内部分学者提出了肿瘤远切缘不规则设计的策略,虽手术命名各不相同,但保留肿瘤对侧肠管的策略殊途同归。在系统总结上述术式与临床实践结果的基础上,笔者提出“远切缘不规则(适形)切除”是实现功能保肛的核心策略之一,强调基于个体化与适形化的肿瘤切除与肠管吻合可能是突破当前困境的关键方向。

    极低位直肠癌的外科治疗长期以来面临着肿瘤根治与肛门功能保留的难题,腹会阴联合切除术(abdominoperineal resection,APR)是该疾病的标准术式,虽能确保肿瘤根治效果,但永久性结肠造口会严重影响患者的心理状态与生活质量[6]。随着经括约肌间切除术(intersphincteric resection,ISR)的推广应用,极低位直肠癌的保肛率得到显著提升,彻底改变了传统治疗格局,即使是局部晚期极低位直肠癌患者,经过新辅助治疗后实施ISR,仍能获得与APR相似的肿瘤学结局[7]。

    ISR可突破传统保肛界限、提升保肛率且肿瘤学结局不劣于APR[8-9],已成为当前临床最广泛使用的低位保肛术式。然而,其全周等距切除的手术固有模式存在明显局限,易造成非肿瘤侧正常组织的不必要损伤,导致术后肛门功能障碍,如便频、便急、肛门失禁(尤其是完全ISR术后),并且低位前切除术综合征(low anterior resection syndrome,LARS)的发生率较高,部分患者的生活质量甚至可能不及APR术后患者[10-12]。研究表明,ISR术后患者的Wexner肛门失禁评分常超过10分(中度至重度失禁),LARS发生率可高达60%~80%,部分患者甚至因严重的肛门功能障碍需重新行永久性结肠造口[13-14]。ISR术后较高的肛门功能障碍发生率充分说明,解剖学上的保肛成功并不等同于功能学上的治疗成功。这一矛盾促使临床实践从追求解剖学保肛率的提升转向对术后肛门功能质量的追求,即实现从“保肛”到“保功能”的转变。

    功能保肛并非简单意义上的保留肛门外形,而是指在彻底切除肿瘤的基础上,最大程度地保留肛门括约肌的解剖结构完整性及神经支配功能,使患者术后能够获得满意的控便功能和生活质量,强调“根治性”与“功能性”的兼顾。评估保肛手术成功与否,除肿瘤学结局外,更应涵盖术后肛门功能的Wexner肛门失禁评分等客观指标和生活质量调查量表结果,后者已成为功能保肛价值的核心体现[15]。由此,极低位直肠癌手术需由单纯扩大切除模式向个体化精准切除转变,而远切缘不规则(适形)切除理念的提出为破解这一临床矛盾提供了新的思路与可行路径。

    远切缘不规则(适形)切除是针对极低位直肠癌设计的个体化精准手术策略,该术式依据肿瘤位置、浸润深度、分化程度及新辅助治疗后退缩情况差异化设计远端切缘,在肿瘤侧保证规范安全边界以实现R0切除,而非肿瘤侧最大化保留正常肠壁、括约肌及神经组织,最终实现肿瘤根治与肛门功能保护的双重目标。

    远端不规则(适形)切除的提出得益于对新辅助治疗后安全切缘的深入研究。切缘的概念包括远端切缘、近端切缘与环周切缘。环周切缘距离>1 mm已被公认为安全的周边界[16],在国内外学者中已达成共识。然而,安全的远端切缘距离范围尚存争议。研究表明,与远端切缘距离>1 cm相比,远端切缘距离≤1 cm对中低位直肠癌患者的总生存期无显著影响,并且在接受新辅助治疗的亚组中远端切缘距离≤1 cm对局部复发率亦无显著影响[17]。另一项研究表明,在新辅助治疗后实现R0切除的中低位直肠癌患者中,即使远端切缘距离<1 cm也不会影响肿瘤学结局[18]。综上所述,对于接受新辅助治疗的直肠癌患者,1 cm的远端切缘距离是安全的,结合术中冰冻病理评估甚至可进一步缩短远端切缘距离。这为远端不规则(适形)切除策略保留更多的肠道及括约肌组织以改善术后肛门功能提供了依据[19-20]。

    远端不规则(适形)切除实现功能保肛的解剖学基础在于对肛门内括约肌及其支配神经的合理保留。该结构承担约70%~85%的肛管静息压,是维持肛管静息压的关键组织,其完整性对控便功能具有决定性作用。ISR为追求足够远端切缘距离,往往需平行甚至广泛切除肿瘤对侧正常的肛门内括约肌,从而导致肛管压力机制受损[21]。此外,括约肌间沟内存在联合纵肌穿行及肛门神经末梢分布,该区域的手术分离亦可能进一步加重组织创伤和神经损伤,从而加剧术后排便控制障碍[22]。

    自2014年由张卫团队首次系统报道基于不规则切除策略的适形切除保肛手术(conformal sphincter preservation operation,CSPO)[23]以来,一系列遵循相同理念的术式相继涌现(图 1),并从吻合技术、经肛操作视野、潜在转移切除、并发症防治等方面不断提出新的见解,显著改善了极低位直肠癌患者的术后肛门功能与远期预后。

    图  1  部分创新远切缘不规则(适形)设计功能保肛术式示意图
    Fig.  1  Schematic diagram of several innovative functional sphincter-preserving procedures with irregular (conformal) distal-margin resection
    ISR: Intersphincteric resection; CSR: Conformal sphincter resection; CSPO: Conformal sphincter preservation operation; CPSP: Conformal proctectomy with sphincter preservation.
    下载: 全尺寸图片

    2014年,张卫团队首次系统提出CSPO术式,其核心理念为“肿瘤靶向切除,功能最大化保留”[23]。该术式依据肿瘤三维形态与浸润范围,在确保R0切除的前提下,通过非对称、不规则切除方式,最大程度地保留了正常直肠壁、肛门内括约肌、齿状线及盆底神经肌肉组织[24]。CSPO的关键在于在直视下依据肿瘤位置与形态设计不规则切除边界,确保肿瘤远端及环周切缘距离均达到1 cm以上,并在肿瘤对侧尽可能保留内括约肌及齿状线[25]。与传统ISR相比,CSPO的创新之处在于其远切缘不规则(适形)切除策略,避免了对无瘤区域括约肌结构的非必要损伤。研究表明,接受CSPO的极低位直肠癌患者术后无病生存期和总生存期与接受APR、低位前切除术、ISR的患者相当,提示其肿瘤学结局的安全性,但CSPO组患者术后肛门功能和生活质量满意度明显优于ISR组,彰显了不规则(适形)切除策略在极低位直肠癌保肛手术中的应用前景[26-28]。

    2019年刘忠诚团队提出了NOSES-PPS术式[29]。该术式在精准功能保肛术(precision functional sphincter-preserving surgery,PPS)的基础上,融合了经自然腔道取标本的方法,兼具理念和器械创新,有效解决了传统经肛操作中视野暴露困难、切除与吻合精度不足的问题。通过创新性地引入透明螺纹扩肛器与经肛微创手术系统,显著改善了术中视野,实现了肿瘤下缘的精确定位与切除,从而最大限度保留正常的肛门内括约肌组织[30]。既往研究表明,NOSES-PPS较传统保肛手术能有效提高保肛率和术后肛门功能,同时降低预防性造口和术后并发症发生率,显示出安全性和有效性[31]。

    2023年项建斌团队提出CSR术式,将不规则切除策略的应用范围进一步扩展至齿状线甚至Hilton白线区域的极低位直肠癌。该术式通过在肿瘤侧扩大切除范围(包括部分外括约肌皮下部及肛周皮肤),并经术中冰冻病理确认切缘阴性,以确保肿瘤学安全性;同时,最大限度保留对侧齿状线黏膜与内括约肌,以实现良好的术后肛门功能[32]。2025年,该团队进一步研究发现括约肌间隙存在潜在肿瘤转移风险,首次提出并定义“括约肌间复合体”(intersphincteric complex,ISC)概念,证实经CSR完整切除该结构有助于改善肿瘤学结局,且未对肛门功能造成显著影响;研究还发现ISC区域内副交感神经分布密集,再次验证了保留肛门内括约肌及括约肌间隙对术后肛门功能的关键作用,突出了远切缘不规则(适形)切除策略在保肛手术中的临床必要性[33]。

    2024年林国乐团队报道了CPSP术式,强调在切除肿瘤过程中,切割线与齿状线需保持约45°夹角,以避免因角度过小(<30°)导致直肠壁保留不足,或角度过大(>60°)引发血供障碍从而增加吻合口漏风险[34]。这一精确的解剖操作原则与远切缘不规则(适形)切除策略所倡导的个体化、适形化切除理念高度一致,以45°角实施的斜行切除不仅在技术上实现了标准化与简化,也降低了手术操作难度和学习曲线,有助于青年外科医师更快掌握;然而,该策略在处理位置极低的直肠癌时可能仍存在一定局限性。此外,该研究通过临床实践为如何规避不规则切除可能带来的吻合口相关并发症提供了一定的启示,尤其在血供保护与吻合张力控制方面具有参考价值。

    2025年汤坚强团队报道了EP-CSPO术式,该术式在CSPO基础上,充分考量了极低位直肠癌保肛手术中吻合口高度对术后功能的影响以及经肛操作视野暴露困难两个问题。EP-CSPO通过充分游离括约肌间隙,将远端直肠及肛管整体外翻,使术者能够在直视下完成对肿瘤侧部分齿状线及肛管全层的精准切除,并依据不规则切除理念,采用“纵切横缝”方式重建内括约肌结构,在最大限度保留功能单位的同时有效提高吻合口高度以实现功能保肛[35]。此外,术中通过对括约肌间隙的充分游离可显著降低吻合口张力,进而减少了吻合口漏等并发症的发生;然而,由于该术式临床应用时间尚短,样本量有限,且未纳入新辅助治疗患者,其长期肿瘤学安全性(如局部复发控制与患者生存效益)尚需通过更多大样本、多中心的前瞻性研究进一步验证。

    2025年李绍堂等于第十届中国医师协会结直肠肿瘤专业委员会学术年会上口头报道了ppISR术式。该团队通过对不同T分期肿瘤壁内扩散距离的病理研究发现,肛提肌水平以下的T1~2期直肠癌壁内侵犯距离不超过5 mm、T3期直肠癌壁内侵犯距离不超过10 mm,从而设计了根据不同分期肿瘤采取不同切缘距离的ppISR方案。该术式同样体现了不规则切除理念,经肛操作时按肿瘤分期设计距离为5~10 mm的“U”形切缘向上游离并经腹汇合、离断,最大程度保留内括约肌及其复合体,再通过修整近端肠管后采取“U”形嵌入吻合重建或皮瓣转移移植,从而取得了良好的术后肛门功能和肿瘤学结局。基于病理学研究的支持,ppISR创新性地将T1~2期直肠癌的远端切缘距离标准缩短至5 mm,在确保肿瘤学安全性的前提下显著扩大了手术适应证,充分体现了精准外科的治疗理念(目前尚未见正式发表资料)。

    2025年李大卫等提出了Q-ISR这一新的保肛术式,该术式将肛管以截石位视角分为“圆”的4个象限,通过括约肌间隙切除肿瘤所在象限的内括约肌,以实现肿瘤学根治;同时,自齿状线向近端沿黏膜下层进行分离,从而完整保留对侧象限的内括约肌及其神经支配。肿瘤侧与非肿瘤侧的不同分离平面最终在肛管直肠环水平汇合,完成肠管离断与手工吻合。由于最大限度地保留了非肿瘤象限的内括约肌及功能复合体结构,Q-ISR在肛门功能保留方面较传统ISR具有显著优势。该术式不仅延续了不规则切除理念,更通过明确划分切除范围实现了手术的规范化和操作流程的简化,有利于临床推广与应用(目前尚未见正式发表资料)。

    除前述术式(理念创新和技术要点见表 1)外,学界仍在不断探索基于不规则切除理念的功能性保肛术式。例如王振军团队提出的改良部分ISR(modified partial intersphincteric resection)[36]、周海洋等提出的腹腔镜辅助改良ISR(laparoscopic-assisted modified intersphincter resection)[37],均从不同的解剖与操作角度对ISR进行了优化,进一步丰富了个体化保肛策略的选择。随着技术理念持续创新与手术器械不断发展,未来有望涌现出更多基于形态与功能双重考量、贯彻精准外科理念的保肛术式,推动功能保肛领域迈向新的高峰。

    表  1  基于ISR的创新功能保肛术式
    Table  1  Innovative functional sphincter-preserving procedures based on ISR
    Procedure Proposer (year) Core concept & innovation Technical key point
    CSPO Zhang Wei (2014) First proposing irregular (conformal) distal margin resection concept for tumor targeted resection and maximizing functional preservation Designing resection margins by tumor location under direct vision, ensuring ≥1 cm safe margin with maximal preservation of contralateral normal tissue[25]
    NOSES-PPS Liu Zhongcheng (2019) Combining NOSES with sphincter-preserving principles and improving transanal visualization via instrumental innovation Employing transparent threaded anal dilator and L’s TAM system for precise inferior tumor margin localization and resection[30]
    CSR Xiang Jianbin (2023) Extending irregular resection strategy below dentate line and introducing ISC concept Performing extended resection on tumor bearing side with maximal contralateral preservation; emphasizing complete ISC excision for better oncological outcomes[32-33]
    CPSP Lin Guole (2024) Standardizing the irregular resection angle (about 45°) to balance tissue preservation and blood supply Aligning resection line at about 45° to dentate line to avoid insufficient preservation or blood supply impairment[34]
    EP-CSPO Tang Jianqiang (2025) Resolving visual field limitations via anal eversion and mitigating functional impacts of anastomotic height through irregular resection Everting anal canal after intersphincteric space dissection for precise direct vision resection; applying “longitudinal cut transverse suture” reconstruction to elevate anastomotic height[35]
    ppISR Li Shaotang (2025) Performing quantitatively precise irregular resection using tumor T stage based intramural invasion data Setting distal resection margin by T stage (T1-2: 5 mm; T3: 10 mm); performing “U” shaped mobilization with imbricated anastomosis/flap graft reconstruction
    Q-ISR Li Dawei (2025) Planning bowel via circular quadrant view to define and simplify irregular resection scope Excising internal sphincter of tumor involved quadrant; preserving sphincter and nerve plexus in non-tumor quadrants via submucosal dissection
    ISR: Intersphincteric resection; CSPO: Conformal sphincter preservation operation; NOSES-PPS: Natural orifice specimen extraction surgery-precision functional sphincter-preserving surgery; CSR: Conformal sphincter resection; CPSP: Conformal proctectomy with sphincter preservation; EP-CSPO: Eversion and plasty-conformal sphincter preservation operation; ppISR: Precision partial intersphincteric resection; Q-ISR: Quadrant intersphincteric resection; NOSES: Natural orifice specimen extraction surgery; ISC: Intersphincteric complex; L’s TAM: Liu’s transanal microsurgery.

    远切缘不规则(适形)切除策略的提出和应用是功能保肛手术领域的一项创新与突破,极大地解决了极低位直肠癌功能保肛的临床困境与核心矛盾。该策略核心理念在于摒弃ISR中环形、对称性切除的固有模式,转而强调基于肿瘤三维浸润范围及个体解剖差异,实施个体化、适形化的肿瘤切除与肠管重建。对于肿瘤位于齿状线以上的患者,远切缘不规则(适形)切除有助于保留更多肛门内括约肌、减少括约肌间隙的游离范围,从而提高术后肛门功能,接受CSPO、CPSP、ppISR等治疗的患者术后肛门功能评分显著优于ISR,体现了该策略的功能保护优势。但值得注意的是,ISC可能存在潜在的肿瘤转移风险,故需更长周期的随访数据或更高证据等级的临床研究以证实肿瘤学安全性。对于肿瘤侵犯齿状线以下的情况,该策略可通过提高吻合口高度减少术后肛门功能障碍的发生风险。一项多中心横断面研究表明,吻合口高度与术后肛门失禁、LARS发生率呈负相关[38]。因此,如EP-CSPO术式所展示,通过不规则(适形)切除尽可能提高吻合口与肛缘的距离,可作为改善术后肛门功能的方法之一。

    随着新辅助治疗和免疫治疗的广泛应用,远切缘不规则(适形)切除策略的适用性和可行性得到了显著拓展[39]。对于初始评估无法保肛的局部晚期极低位直肠癌,新辅助治疗可实现肿瘤降期和体积退缩,从而为实施不规则切除提供解剖学条件,使根治性切除与功能保留得以实现[40]。然而,新辅助治疗也可能导致盆腔纤维化、组织水肿及解剖结构模糊,进而损害括约肌的神经支配与肌纤维完整性,增加术后肛门功能障碍的风险[41-43]。远切缘不规则(适形)切除策略能最大限度保留括约肌组织、齿状线及肛垫结构,从而有效抵消治疗引起的功能损害,最大程度维持肛管静息压与控便功能。新辅助治疗后肿瘤退缩模式呈现高度异质性,包括肿瘤退缩、碎片化或黏液湖形成等,传统规则性切除恐难以应对此类复杂情况[44]。不规则切除策略所具有的灵活性与适形性使其能够依据肿瘤残留范围及边界动态调整切除平面,在确保肿瘤根治性的同时,最大程度保全肛门功能。

    功能保肛是患者与外科医生共同追求的核心目标。随着对直肠及盆底解剖结构认识的深化、新辅助治疗技术的广泛应用、手术器械的持续革新,远切缘不规则(适形)切除的理念应运而生,并逐渐成为实现功能保肛的关键策略。该理念并非对传统术式的否定,而是在其基础上的优化与发展,共同推动保肛手术从解剖极限迈向功能极致。

    然而,远切缘不规则(适形)切除策略并非保肛技术的终点。括约肌复合体的精细解剖与神经调节机制、新辅助治疗对术后肛门功能的影响[45]、免疫治疗时代保肛策略的演变[46]、高级别循证医学证据的积累等,仍是当前亟待深入研究的关键问题。此外,人工智能辅助技术和新型手术器械的研发及其与个体化多学科诊疗模式的深度融合,均将持续影响并推动保肛策略的演进。功能保肛的发展永无止境。

  • 图  1   部分创新远切缘不规则(适形)设计功能保肛术式示意图

    Fig.  1   Schematic diagram of several innovative functional sphincter-preserving procedures with irregular (conformal) distal-margin resection

    ISR: Intersphincteric resection; CSR: Conformal sphincter resection; CSPO: Conformal sphincter preservation operation; CPSP: Conformal proctectomy with sphincter preservation.

    下载: 全尺寸图片

    表  1   基于ISR的创新功能保肛术式

    Table  1   Innovative functional sphincter-preserving procedures based on ISR

    Procedure Proposer (year) Core concept & innovation Technical key point
    CSPO Zhang Wei (2014) First proposing irregular (conformal) distal margin resection concept for tumor targeted resection and maximizing functional preservation Designing resection margins by tumor location under direct vision, ensuring ≥1 cm safe margin with maximal preservation of contralateral normal tissue[25]
    NOSES-PPS Liu Zhongcheng (2019) Combining NOSES with sphincter-preserving principles and improving transanal visualization via instrumental innovation Employing transparent threaded anal dilator and L’s TAM system for precise inferior tumor margin localization and resection[30]
    CSR Xiang Jianbin (2023) Extending irregular resection strategy below dentate line and introducing ISC concept Performing extended resection on tumor bearing side with maximal contralateral preservation; emphasizing complete ISC excision for better oncological outcomes[32-33]
    CPSP Lin Guole (2024) Standardizing the irregular resection angle (about 45°) to balance tissue preservation and blood supply Aligning resection line at about 45° to dentate line to avoid insufficient preservation or blood supply impairment[34]
    EP-CSPO Tang Jianqiang (2025) Resolving visual field limitations via anal eversion and mitigating functional impacts of anastomotic height through irregular resection Everting anal canal after intersphincteric space dissection for precise direct vision resection; applying “longitudinal cut transverse suture” reconstruction to elevate anastomotic height[35]
    ppISR Li Shaotang (2025) Performing quantitatively precise irregular resection using tumor T stage based intramural invasion data Setting distal resection margin by T stage (T1-2: 5 mm; T3: 10 mm); performing “U” shaped mobilization with imbricated anastomosis/flap graft reconstruction
    Q-ISR Li Dawei (2025) Planning bowel via circular quadrant view to define and simplify irregular resection scope Excising internal sphincter of tumor involved quadrant; preserving sphincter and nerve plexus in non-tumor quadrants via submucosal dissection
    ISR: Intersphincteric resection; CSPO: Conformal sphincter preservation operation; NOSES-PPS: Natural orifice specimen extraction surgery-precision functional sphincter-preserving surgery; CSR: Conformal sphincter resection; CPSP: Conformal proctectomy with sphincter preservation; EP-CSPO: Eversion and plasty-conformal sphincter preservation operation; ppISR: Precision partial intersphincteric resection; Q-ISR: Quadrant intersphincteric resection; NOSES: Natural orifice specimen extraction surgery; ISC: Intersphincteric complex; L’s TAM: Liu’s transanal microsurgery.
  • [1] Lee L, Trepanier M, Renaud J, et al. Patients' preferences for sphincter preservation versus abdominoperineal resection for low rectal cancer[J]. Surgery, 2021, 169(3):623-628. DOI: 10.1016/j.surg.2020.07.020.
    [2] Kagawa Y, Smith J J, Fokas E, et al. Future direction of total neoadjuvant therapy for locally advanced rectal cancer[J]. Nat Rev Gastroenterol Hepatol, 2024, 21(6): 444-455. DOI: 10.1038/s41575-024-00900-9.
    [3] Noiret B, Koo C H, Bacci M, et al. Clinical contexts for shared decision-making in rectal cancer: organ preservation, sphincter-sparing surgery and tailored stoma policy[J]. Eur J Surg Oncol, 2025, 51(9): 110196. DOI: 10.1016/j.ejso.2025.110196.
    [4] Wu F, Shen X. Clinical progress and technological innovations in sphincter-preserving treatment for ultra-low rectal cancer[J]. Front Oncol, 2026, 16: 1685145. DOI: 10.3389/fonc.2026.1685145.
    [5] Wang C, Liu X, Wang W, et al. Treatment options for distal rectal cancer in the era of organ preservation[J]. Curr Treat Options Oncol, 2024, 25(4): 434-452. DOI: 10.1007/s11864-024-01194-4.
    [6] Kang S B, Cho J R, Jeong S Y, et al. Quality of life after sphincter preservation surgery or abdominoperineal resection for low rectal cancer (ASPIRE): a long-term prospective, multicentre, cohort study[J]. Lancet Reg Health West Pac, 2021, 6: 100087. DOI: 10.1016/j.lanwpc.2020.100087.
    [7] Shin J K, Kim H C, Lee W Y, et al. Sphincter-saving surgery versus abdominoperineal resection in low rectal cancer following neoadjuvant treatment with propensity score analysis[J]. Surg Endosc, 2022, 36(4): 2623-2630. DOI: 10.1007/s00464-021-08558-z.
    [8] Wang G C, Chen J X, Pan H F, et al. Long-term efficacy and short-term outcomes of intersphincteric resection vs abdominoperineal resection in patients with ultra-low rectal cancer[J]. World J Gastroenterol, 2025, 31(29): 110004. DOI: 10.3748/wjg.v31.i29.110004.
    [9] Ramezani Z, Madankan A, Baigi V, et al. Intersphincteric resection versus abdominoperineal resection for lower rectal cancer: a systematic review and meta-analysis[J]. Surg Oncol, 2026, 68: 102502. DOI: 10.1016/j.suronc.2026.102502.
    [10] Emmertsen K J, Laurberg S. Low anterior resection syndrome score: development and validation of a symptom-based scoring system for bowel dysfunction after low anterior resection for rectal cancer[J]. Ann Surg, 2012, 255(5): 922-928. DOI: 10.1097/SLA.0b013e31824f1c21.
    [11] Celerier B, Denost Q, van Geluwe B, et al. The risk of definitive stoma formation at 10 years after low and ultralow anterior resection for rectal cancer[J]. Colorectal Dis, 2016, 18(1): 59-66. DOI: 10.1111/codi.13124.
    [12] Denost Q, Moreau J B, Vendrely V, et al. Intersphincteric resection for low rectal cancer: the risk is functional rather than oncological. A 25-year experience from Bordeaux[J]. Colorectal Dis, 2020, 22(11): 1603-1613. DOI: 10.1111/codi.15258.
    [13] Denost Q, Laurent C, Capdepont M, et al. Risk factors for fecal incontinence after intersphincteric resection for rectal cancer[J]. Dis Colon Rectum, 2011, 54(8): 963-968. DOI: 10.1097/DCR.0b013e31821d3677.
    [14] Klose J, Tarantino I, Kulu Y, et al. Sphincter-preserving surgery for low rectal cancer: do we overshoot the mark?[J]. J Gastrointest Surg, 2017, 21(5): 885-891. DOI: 10.1007/s11605-016-3339-0.
    [15] Wexner S D. Further validation of the Wexner incontinence score: a note of appreciation and gratitude[J]. Surgery, 2021, 170(1): 53-54. DOI: 10.1016/j.surg.2021.02.039.
    [16] Agger E A, Jörgren F H, Lydrup M A, et al. Risk of local recurrence of rectal cancer and circumferential resection margin: population-based cohort study[J]. Br J Surg, 2020, 107(5): 580-585. DOI: 10.1002/bjs.11478.
    [17] Yan H, Wang P Y, Wu Y C, et al. Is a distal resection margin of ≤ 1 cm safe in patients with intermediate- to low-lying rectal cancer? A systematic review and meta-analysis[J]. J Gastrointest Surg, 2022, 26(8): 1791-1803. DOI: 10.1007/s11605-022-05342-9.
    [18] Manegold P, Taukert J, Neeff H, et al. The minimum distal resection margin in rectal cancer surgery and its impact on local recurrence: a retrospective cohort analysis[J]. Int J Surg, 2019, 69: 77-83. DOI: 10.1016/j.ijsu.2019.07.029.
    [19] Yu G, Chi H, Zhao G, et al. Tumor regression and safe distance of distal margin after neoadjuvant therapy for rectal cancer[J]. Front Oncol, 2024, 14: 1375334. DOI: 10.3389/fonc.2024.1375334.
    [20] Luo J, Zhu M, Zhao L, et al. Distal margin distance in radical resection of locally advanced rectal cancer after neoadjuvant therapy[J]. Chung Kuo Yen Cheng Yen Chiu, 2024, 36(2): 226-232. DOI: 10.21147/j.issn.1000-9604.2024.02.09.
    [21] 张卫, 朱晓明. 极低位直肠癌经括约肌间切除术的分类及其优势与局限性[J]. 中华胃肠外科杂志, 2023, 26(6): 557-561. DOI: 10.3760/cma.j.cn441530-20230603-00191.
    [22] Hieda K, Cho K H, Arakawa T, et al. Nerves in the intersphincteric space of the human anal canal with special reference to their continuation to the enteric nerve plexus of the rectum[J]. Clin Anat, 2013, 26(7): 843-854. DOI: 10.1002/ca.22227.
    [23] 楼征, 何建, 朱晓明, 等. 腹腔镜联合经肛门拖出适形切除术治疗极低位直肠癌初步报道[J]. 外科理论与实践, 2014, 19(6): 493-496. DOI: 10.3969/j.issn.1007-9610.2014.06.007.
    [24] 楼征, 张卫. 超低位直肠癌适形保肛手术之经肛适形切除术[J]. 中华胃肠外科杂志, 2018, 21(3): 246-249. DOI: 10.3760/cma.j.issn.1671-0274.2018.03.002.
    [25] 中华医学会外科学分会结直肠外科学组, 中国医师协会结直肠肿瘤专业委员会, 中国医师协会肛肠医师分会. 低位直肠癌适形保肛手术操作标准(2023版)[J]. 中华胃肠外科杂志, 2023, 26(10): 907-914. DOI: 10.3760/cma.j.cn441530-20230829-00073.
    [26] Sun G, Lou Z, Zhang H, et al. Retrospective study of the functional and oncological outcomes of conformal sphincter preservation operation in the treatment of very low rectal cancer[J]. Tech Coloproctol, 2020, 24(10): 1025-1034. DOI: 10.1007/s10151-020-02229-2.
    [27] Sun G, Lou Z, Zheng K, et al. Comparison of functional and oncological outcome of conformal sphincter preservation operation, low anterior resection, and abdominoperineal resection in very low rectal cancer: a retrospective comparative cohort study with propensity score matching[J]. Langenbecks Arch Surg, 2023, 408(1): 208. DOI: 10.1007/s00423-023-02925-1.
    [28] Sun G, Zang Y, Ding H, et al. Comparison of anal function and quality of life after conformal sphincter preservation operation and intersphincteric resection of very low rectal cancer: a multicenter, retrospective, case-control analysis[J]. Tech Coloproctol, 2023, 27(12): 1275-1287. DOI: 10.1007/s10151-023-02819-w.
    [29] 庄成乐, 张现中, 刘骞, 等. 基于一种螺纹扩肛器的超低位直肠癌精准保肛(PPS)手术[J]. 中华结直肠疾病电子杂志, 2019, 8(5): 509-512. DOI: 10.3877/cma.j.issn.2095-3224.2019.05.014.
    [30] 中国医师协会结直肠肿瘤专业委员会, 中国抗癌协会大肠癌专业委员会, 中国NOSES研究协作组, 等. 经自然腔道取标本之超低位直肠癌精准功能保肛(NOSES-PPS)手术操作标准(2024版)[J/OL]. 消化肿瘤杂志(电子版), 2025, 17(1): 9-15. DOI: 10.3760/cma.j.cn441530-20240828-00295.
    [31] Zhuang C L, Zhang F M, Wang Z, et al. Precision functional sphincter-preserving surgery (PPS) for ultralow rectal cancer: a natural orifice specimen extraction (NOSE) surgery technique[J]. Surg Endosc, 2021, 35(1): 476-485. DOI: 10.1007/s00464-020-07989-4.
    [32] Zhou Y M, Zang Y W, Li Z Y, et al. Conformal sphincteric resection for ultra-low rectal cancer located below the dentate line: a pilot report[J]. Colorectal Dis, 2023, 25(12): 2414-2422. DOI: 10.1111/codi.16776.
    [33] Yan S, Zhou M, Zhou Y, et al. Intersphincteric complex a potential metastasis niche in ultralow rectal cancer and prognostic significance of its complete excision following intersphincteric resection: a prospective cohort study[J]. Int J Surg, 2025, 111(7): 4434-4442. DOI: 10.1097/JS9.0000000000002487.
    [34] Chen W, Zhang X, Qiu X, et al. Conformal proctectomy with sphincter preservation retains acceptable defecation functions in very low rectal cancer male patients[J]. Front Oncol, 2024, 14: 1478467. DOI: 10.3389/fonc.2024.1478467.
    [35] 胡刚, 邢兆东, 杜锦波, 等. 全腹腔镜超低位保肛手术中采用外翻视野下切除部分齿状线和肛管全层安全性及有效性研究[J]. 中国实用外科杂志, 2025, 45(7): 806-811. DOI: 10.19538/j.cjps.issn1005-2208.2025.07.15.
    [36] Han J G, Wei G H, Gao Z G, et al. Intersphincteric resection with direct coloanal anastomosis for ultralow rectal cancer: the experience of People's Republic of China[J]. Dis Colon Rectum, 2009, 52(5): 950-957. DOI: 10.1007/DCR.0b013e31819f13a3.
    [37] Zhou H, Ruan C, Wang Z, et al. Laparoscopic-assisted modified intersphincter resection for ultralow rectal cancer[J]. Ann Surg Oncol, 2018, 25(4): 947-948. DOI: 10.1245/s10434-017-6280-x.
    [38] Verkuijl S J, Hoff C, Furnée E J B, et al. Anastomotic height is a valuable indicator of long-term bowel function following surgery for rectal cancer[J]. Dis Colon Rectum, 2023, 66(2): 221-232. DOI: 10.1097/DCR.0000000000002168.
    [39] Zhou L, Yu G, Shen Y, et al. Safety and clinical efficacy of neoadjuvant chemoradiation therapy with immunotherapy for organ preservation in ultra-low rectal cancer: preliminary results of the CHOICE-I trial: a prospective cohort study[J]. Int J Surg, 2025, 111(3): 2487-2494. DOI: 10.1097/js9.0000000000002225.
    [40] Yuval J B, Thompson H M, Garcia-Aguilar J. Organ preservation in rectal cancer[J]. J Gastrointest Surg, 2020, 24(8): 1880-1888. DOI: 10.1007/s11605-020-04583-w.
    [41] Ma B, Gao P, Wang H, et al. What has preoperative radio(chemo)therapy brought to localized rectal cancer patients in terms of perioperative and long-term outcomes over the past decades? A systematic review and meta-analysis based on 41, 121 patients[J]. Int J Cancer, 2017, 141(5): 1052-1065. DOI: 10.1002/ijc.30805.
    [42] Loos M, Quentmeier P, Schuster T, et al. Effect of preoperative radio(chemo)therapy on long-term functional outcome in rectal cancer patients: a systematic review and meta-analysis[J]. Ann Surg Oncol, 2013, 20(6): 1816-1828. DOI: 10.1245/s10434-012-2827-z.
    [43] van der Sande M E, Hupkens B J P, Berbée M, et al. Impact of radiotherapy on anorectal function in patients with rectal cancer following a watch and wait programme[J]. Radiother Oncol, 2019, 132: 79-84. DOI: 10.1016/j.radonc.2018.11.017.
    [44] 王晔, 楼征, 孟荣贵, 等. 直肠癌新辅助治疗后肿瘤退缩模式及远切缘安全距离的研究进展[J]. 中华胃肠外科杂志, 2023, 26(3): 302-306. DOI: 10.3760/cma.j.cn441530-20220627-00280.
    [45] Shi J, Cheng Y K, He F, et al. Effects of neoadjuvant radiochemotherapy for anorectal function in locally advanced rectal cancer patients: a study protocol for a prospective, observational, controlled, multicentre study[J]. BMC Cancer, 2023, 23(1): 467. DOI: 10.1186/s12885-023-10951-x.
    [46] 朱晓明, 张卫. 免疫治疗时代低位直肠癌的保肛治疗策略[J]. 中华消化外科杂志, 2024, 23(6): 795-800. DOI: 10.3760/cma.j.cn115610-20240317-00159.
WeChat 点击查看大图
图(1)  /  表(1)
出版历程
  • 收稿日期:  2026-03-24
  • 接受日期:  2026-07-02
  • 优先发表日期:  2026-09-24

目录

    /

    返回文章
    返回